Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies in patients with locally advanced or metastatic platinum-resistant urothelial carcinoma.
To compare the real-life experience and data of clinical trials on ATZ treatment in metastatic urothelial carcinoma.